Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMMONIUM CHLORIDE 2.14% vs ACULAR LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ammonium chloride is an acidifying agent. It dissociates into ammonium and chloride ions. The ammonium ion is metabolized in the liver to urea and hydrogen ions, leading to metabolic acidosis. This reduces blood p H and increases renal excretion of alkaline urine.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Treatment of metabolic alkalosis,Urinary acidification to enhance excretion of weak bases (e.g., amphetamines, quinidine) or to promote dissolution of calcium phosphate stones
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
For metabolic alkalosis: 1.5 to 3 g (approximately 280 to 560 m Eq) intravenously over 4 to 6 hours; adjust based on serum chloride and p H.
1 drop in the affected eye(s) four times daily
4-6 hours; prolonged in renal impairment (up to 12-15 hours).
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Converted to urea and hydrogen ions in the liver via the urea cycle.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Renal: >99% as ammonium ion and chloride; minimal biliary/fecal elimination.
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
Negligible (<1%); not significantly bound to plasma proteins.
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg; distributes primarily in extracellular fluid; clinical meaning: low Vd reflects limited tissue penetration.
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: 100% (fully absorbed); IV: 100%; topical: non-systemic.
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 50% and monitor serum electrolytes. For GFR >60 m L/min: no adjustment.
No dosage adjustment required for renal impairment
No specific Child-Pugh based adjustment; use caution in severe hepatic impairment due to risk of ammonia toxicity.
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
Neonates and children: 1-2 m Eq/kg intravenously per dose, infused over 2-4 hours; maximum 100 m Eq per dose. Titrate based on serum chloride and acid-base status.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
Start at lower end of adult dosing (e.g., 1.5 g intravenously) due to age-related decreased renal function; monitor electrolytes and renal function closely.
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
None
None
Avoid in patients with impaired renal or hepatic function; may cause hyperammonemia and hepatic coma.,Use with caution in patients with cardiac failure or pulmonary edema due to risk of fluid overload.,Monitor serum chloride, bicarbonate, and p H levels during therapy.
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
Severe hepatic insufficiency,Severe renal impairment,Hyperammonemia,Uremia,Ammonium toxicity
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
No significant food interactions known. However, a diet low in chloride may reduce efficacy. Avoid excessive intake of alkalinizing foods (e.g., citrus fruits, vegetables) that may counteract the acidifying effect.
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
Ammonium chloride is not known to be teratogenic in humans. No structural anomalies have been reported with first trimester exposure. In second and third trimesters, maternal acidosis from excessive dosing could potentially affect fetal acid-base balance, but no specific fetal risks are documented. Overall, classified as FDA Pregnancy Category C.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
Excretion into breast milk is unknown. M/P ratio not available. Caution advised due to potential for neonatal acidosis if maternal doses are high. Short-term use is likely compatible with breastfeeding.
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
No specific dosing adjustments required in pregnancy. However, due to pregnancy-associated hyperventilation and renal changes, monitor acid-base status. Initiate at low doses and titrate based on serum chloride and bicarbonate levels.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
Ammonium chloride 2.14% is a systemic acidifying agent used to treat metabolic alkalosis. Monitor serum electrolytes (especially chloride and bicarbonate) and arterial blood gases closely. Avoid in patients with severe hepatic or renal impairment, as ammonium ions can precipitate hepatic encephalopathy or worsen acidosis. Infuse slowly to prevent hemolysis. Use with caution in patients with respiratory acidosis.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
This medication is used to treat low acid levels in the blood.,Your healthcare provider will monitor your blood tests regularly while on this medicine.,Report any signs of allergic reaction (rash, itching, swelling) or symptoms of acidosis (confusion, rapid breathing) immediately.,Avoid taking other medications or supplements without consulting your doctor, as they may interfere with this treatment.,Do not stop this medication abruptly without medical advice.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMMONIUM CHLORIDE 2.14% vs ACULAR LS, answered by our medical review team.
AMMONIUM CHLORIDE 2.14% is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent. It dissociates into ammonium and chloride ions. The ammonium ion is metabolized in the liver to urea and hydrogen ions, leading to metabolic acidosis. This reduces blood p H and increases renal excretion of alkaline urine.. ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMMONIUM CHLORIDE 2.14% and ACULAR LS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMMONIUM CHLORIDE 2.14% is: For metabolic alkalosis: 1.5 to 3 g (approximately 280 to 560 m Eq) intravenously over 4 to 6 hours; adjust based on serum chloride and p H.. The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMMONIUM CHLORIDE 2.14% and ACULAR LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMMONIUM CHLORIDE 2.14% is classified as Category C. Ammonium chloride is not known to be teratogenic in humans. No structural anomalies have been reported with first trimester exposure. In second and third trimesters, maternal acido. ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.